



[Home](#) / [Investors](#) / [Press Releases](#)

Insmmed to Host Second Quarter 2015 Financial Results Conference Call on Thursday, August 6, 2015

BRIDGEWATER, N.J., July 28, 2015 (GLOBE NEWSWIRE) -- Insmmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today announced that it will release its financial results for the three months ended June 30, 2015, before the opening of the stock market on Thursday, August 6, 2015.

Will Lewis, president and chief executive officer, and Andy Drechsler, chief financial officer, will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, August 6, 2015 to discuss the second quarter 2015 financial results and to provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing 877-698-3991 (domestic) or 817-522-1636 (international) and referencing conference ID number 92042219. The call will also be webcast live on the internet on the company's website at www.insmed.com.

A replay of the conference call will be accessible two hours after its completion through August 20, 2015 by dialing 855-859-2056 (domestic) or 404-537-3406 (international) and referencing conference ID number 92042219. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmmed

Insmmed Incorporated is a global biopharmaceutical company focused on the needs of patients with rare diseases. The company is advancing a global Phase 3 clinical study of ARIKAYCE™ (liposomal amikacin for inhalation) in nontuberculous (NTM) lung disease, a rare and often chronic infection that can lead to progressive inflammation and lung damage. There are no currently approved treatments for NTM in the United States or European Union (EU). In the EU, the company has filed a marketing authorization application seeking approval of ARIKAYCE for use in patients with NTM, as well as in *Pseudomonas aeruginosa* lung infections in cystic fibrosis patients. Insmmed's earlier-stage pipeline includes INS1009, an inhaled prodrug formulation of treprostinil that the company is developing for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. To complement its internal research, Insmmed actively seeks in-licensing opportunities for a broad range of rare diseases. For more information visit www.insmed.com.
